Early clinical research
MRTX1133 — KRAS G12D-targeted inhibitor (early clinical)
A Phase 1/2 Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Phase
- Phase I
- Recruitment
- Terminated
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT05737706
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? New drugs aimed at the common KRAS G12D change in pancreatic cancer are being tested in early stages.
What did it show? G12D-specific inhibitor program for PDAC stopped early — unmet need remains, but this card makes no efficacy claim.
What is not proven? Clinical efficacy/OS; non-G12D alleles; approved use.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
NCT05737706; recruitment/result status should be re-checked on ClinicalTrials.gov as of 2026-10-29.
Cancer / population: Pancreas, Multiple / solid tumors — KRAS G12D mutant ileri solid tümörler (PDAC ağırlıklı ilgi)
Intervention: MRTX1133
Primary endpoint: Güvenlik / RP2D; antitümör aktivite
Limitations: Erken faz; canlı kayıt durumu editoryal yeniden kontrol ister.